Medical Information
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

ZOLEDRONIC ACID INJECTION - CONCENTRATE FOR INTRAVENOUS INFUSION Highlights (zoledronic acid for injection - CONCENTRATE FOR INTRAVENOUS INFUSION)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ZOLEDRONIC ACID INJECTION safely and effectively. See full prescribing information for ZOLEDRONIC ACID INJECTION.

ZOLEDRONIC ACID INJECTION, for intravenous infusion
Initial U.S. Approval: 2001

RECENT MAJOR CHANGES

Warnings and Precautions, Embryo-Fetal Toxicity (5.10)12/2018

INDICATIONS AND USAGE

Zoledronic acid injection is a bisphosphonate indicated for the treatment of:

  • Hypercalcemia of malignancy. (1.1)
  • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. (1.2)

Limitations of Use: The safety and efficacy of zoledronic acid injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.

DOSAGE AND ADMINISTRATION

Hypercalcemia of malignancy. (2.1)

  • 4 mg as a single-use intravenous infusion over no less than 15 minutes.
  • 4 mg as retreatment after a minimum of 7 days.

Multiple myeloma and bone metastasis from solid tumors. (2.2)

  • 4 mg as a single-use intravenous infusion over no less than 15 minutes every 3–4 weeks for patients with creatinine clearance of greater than 60 mL/min.
  • Reduce the dose for patients with renal impairment.
  • Coadminister oral calcium supplements of 500 mg and a multiple vitamin containing 400 international units of vitamin D daily.

Administer through a separate vented infusion line and do not allow to come in contact with any calcium or divalent cation-containing solutions. (2.3)

DOSAGE FORMS AND STRENGTHS

Injection: 4 mg/5 mL (0.8 mg/mL) single-dose vial for dilution prior to intravenous infusion. (3)

CONTRAINDICATIONS

Hypersensitivity to any component of zoledronic acid injection. (4)

WARNINGS AND PRECAUTIONS

  • Patients being treated with zoledronic acid should not be treated with Reclast®. (5.1)
  • Adequately rehydrate patients with hypercalcemia of malignancy prior to administration of zoledronic acid and monitor electrolytes during treatment. (5.2)
  • Renal toxicity may be greater in patients with renal impairment. Do not use doses greater than 4 mg. Treatment in patients with severe renal impairment is not recommended. Monitor serum creatinine before each dose. (5.3)
  • Osteonecrosis of the jaw (ONJ) has been reported. Preventive dental exams should be performed before starting zoledronic acid. Avoid invasive dental procedures. (5.4)
  • Severe incapacitating bone, joint, and/or muscle pain may occur. Discontinue zoledronic acid if severe symptoms occur. (5.5)
  • Atypical subtrochanteric and diaphyseal femoral fractures have been reported in patients receiving bisphosphonate therapy. These fractures may occur after minimal or no trauma. Evaluate patients with thigh or groin pain to rule out a femoral fracture. Consider drug discontinuation in patients suspected to have an atypical femur fracture. (5.6)
  • Hypocalcemia: Correct before initiating zoledronic acid injection. Adequately supplement patients with calcium and vitamin D. Monitor serum calcium closely with concomitant administration of other drugs known to cause hypocalcemia to avoid severe or life-threatening hypocalcemia. (5.9)
  • Zoledronic acid can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception. (5.10, 8.1, 8.3)

ADVERSE REACTIONS

The most common adverse events (greater than 25%) were nausea, fatigue, anemia, bone pain, constipation, fever, vomiting, and dyspnea. (6.1)


To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc., at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Aminoglycosides: May have an additive effect to lower serum calcium for prolonged periods. (7.1)
  • Loop Diuretics: Concomitant use with zoledronic acid may increase risk of hypocalcemia. (7.2)
  • Nephrotoxic Drugs: Use with caution. (7.3)

USE IN SPECIFIC POPULATIONS

  • Lactation: Advise not to breastfeed. (8.2)
  • Females and Males of Reproductive Potential: Verify pregnancy status prior to initiation of zoledronic acid. May impair fertility. Counsel patients on pregnancy planning and prevention. (8.3)
  • Pediatric Use: Not indicated for use in pediatric patients. (8.4)
  • Geriatric Use: Special care to monitor renal function. (8.5)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 6/2019

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event